View Older Stories View More Recent Stories
-
DexCom (DXCM) PT Lowered to $88 at Bernstein SocGen Group
-
DexCom (DXCM) PT Raised to $109 at BTIG
-
DexCom (DXCM) Misses Q1 EPS by 1c; offers guidance
-
Bernstein Reiterates Outperform Rating on DexCom (DXCM) Following FDA Approval
-
Canaccord Genuity Reiterates Buy Rating on DexCom (DXCM)
-
Raymond James Reiterates Strong Buy Rating on DexCom (DXCM), PT $99, 'we believe the stock should be strong today'
-
Stifel Reiterates Buy Rating on DexCom (DXCM)
-
BTIG Reiterates Buy Rating on DexCom (DXCM)
-
DexCom (DXCM) G7 15 Day Receives FDA Clearance
-
Mizuho Starts DexCom (DXCM) at Outperform
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
DexCom (DXCM) Appoints Jon Coleman as CCO
-
Citi Reiterates Buy Rating on DexCom (DXCM)
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
DexCom (DXCM) Appoints Renée Galá to its Board
-
BTIG Reiterates Buy Rating on DexCom (DXCM)
-
This stock has 'multiple drivers of upside for 2025': analyst
-
Bernstein on DexCom (DXCM): 'Back on Track in 2025?'; PT Raised to $100
-
DexCom (DXCM) Misses Q4 EPS by 7c ; Offers Guidance
-
BofA on DexCom (DXCM): 'a particularly attractive buying opportunity'
-
Redburn-Atlantic Upgrades DexCom (DXCM) to Buy
-
Raymond James Reiterates Strong Buy Rating on DexCom (DXCM)
-
Piper Sandler on DexCom (DXCM): 'We Believe it is Time for Investors to Come Back to the Name'
-
Baird Upgrades DexCom (DXCM) to Outperform
-
Citi Reiterates Buy Rating on DexCom (DXCM)
-
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
4 MedTech stocks to own for 2025: BTIG
-
Is Trump 2.0 good or bad for healthcare stocks?
-
This MedTech stock is the 2025 best idea at BofA
-
BofA Securities Reiterates Buy Rating on DexCom (DXCM), 'A 2025 best idea with a recovery kicker'
-
What's ahead for active funds according to BofA
-
DexCom (DXCM) PT Lowered to $105 at Oppenheimer
-
TD Cowen Reiterates Buy Rating on DexCom (DXCM)
-
Canaccord Genuity Reiterates Buy Rating on DexCom (DXCM)
-
DexCom (DXCM) PT Raised to $86 at Bernstein SocGen Group
-
BTIG Reiterates Buy Rating on DexCom (DXCM)
-
After-hours movers: Capri Holdings, Skechers, DexCom, Western Digital and more
-
DexCom (DXCM) Tops Q3 EPS by 2c, Maintains Guidance
-
Piper Sandler Reiterates Overweight Rating on DexCom (DXCM)
-
Canaccord Genuity Reiterates Buy Rating on DexCom (DXCM)
-
Piper Sandler Reiterates Overweight Rating on DexCom (DXCM)
-
Stifel Reiterates Buy Rating on DexCom (DXCM)
-
Selloff in MedTech stocks 'seems overdone': Citi
-
DexCom (DXCM) PT Lowered to $130 at RBC Capital
-
Global equities to stage a near-term rebound: UBS
-
DexCom (DXCM) PT Raised to $82 at Baird
-
Tandem Diabetes (TNDM) and Dexcom (DXCM) Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada
-
DexCom (DXCM) June 55 and 65 puts active as share price down 41%

